PARP1 and atrial fibrillation: Studies like these might offer insight into the role of dysregulated PARP1-NAD+ signaling in aging and AF and, ultimately, provide innovative strategies for the therapeutic targeting of mitochondrial dysfunction and DNA damage to reduce the burden of age-related AF.